There is a lack of consensus on the role of selective cannabinoids for the treatment of neuropathic pain. Guidelines from national and international pain societies provide contradictory recommendations. A systematic review and meta-analysis published in Anesthesia & Analgesia targeted analgesic efficacy and safety of selective cannabinoids and compared them to conventional management or placebo for chronic neuropathic pain. According to these study results, cannabinoids provide a small benefit for some people with neuropathic pain.
Link to: Anesth Analg article via Medscape (12/2017) (open access with site registration)
